Рецепт. 2021; 24: 822-829
Ингибиторы фосфодиэстеразы 5-го типа в лечении эректильной дисфункции
https://doi.org/10.34883/PI.2021.24.6.005Аннотация
В статье представлен обзор современных представлений об эректильной дисфункции с приведением данных об эпидемиологии и этиологии рассматриваемой проблемы, а также факторах риска. Отдельное внимание уделено актуальным аспектам медикаментозного лечения с применением первой линии терапии ингибиторами фосфодиэстеразы 5-го типа в соответствии с актуальными клиническими рекомендациями, а также с позиции доказательной медицины. Приведен сравнительный обзор одобренных для клинического применения основных формул ингибиторов ФДЭ-5: силденафила, тадалафила, варденафила и аванафила с учетом их клинической эффективности и безопасности. Представлено лекарственное средство из группы суперселективных ингибиторов ФДЭ-5 Аваналав®, его рекомендуемые дозировки и правила применения.
Список литературы
1. Chen L., et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: A trade-off network meta-analysis. Eur Urol, 2015. 68: 674.
2. Corona G. et al. The safety and efficacy of Avanafil, a new generation PDE5i: Comprehensive review and meta-analysis. Expert Opinion on Drug Safety, 2016. 15(2): 237.
3. Salonia A. EAU Guidelines on Sexual and Reproductive Health [Electronic resource]. Eur. Assoc. of Urology. 2021. Mode of access: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Sexual-and-Reproductive-Health-2021.
4. Gratzke C. et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med, 2010. 7: 445.
5. Hatzimouratidis K. et al. Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med, 2016. 13: 465.
6. Yuan J. et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol, 2013. 63: 902.
Recipe. 2021; 24: 822-829
Phosphodiesterase-5 Inhibitors in the Treatment of Erectile Dysfunction
https://doi.org/10.34883/PI.2021.24.6.005Abstract
The article presents an overview of modern ideas about erectile dysfunction with data on the epidemiology, etiology as well as risk factors. Special attention is paid to topical aspects of drug treatment with phosphodiesterase-5 inhibitors as first-line therapy for erectile dysfunction in accordance with current clinical recommendations from the position of evidence-based medicine. A comparative review for clinical efficacy and safety of the main formulas of PDE-5 inhibitors approved for clinical use (sildenafil, tadalafil, vardenafil and avanafil) is given. A drug from the group of selective PDE-5 inhibitors Avanalav® is presented with its recommended dosages and rules of use.
References
1. Chen L., et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: A trade-off network meta-analysis. Eur Urol, 2015. 68: 674.
2. Corona G. et al. The safety and efficacy of Avanafil, a new generation PDE5i: Comprehensive review and meta-analysis. Expert Opinion on Drug Safety, 2016. 15(2): 237.
3. Salonia A. EAU Guidelines on Sexual and Reproductive Health [Electronic resource]. Eur. Assoc. of Urology. 2021. Mode of access: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Sexual-and-Reproductive-Health-2021.
4. Gratzke C. et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med, 2010. 7: 445.
5. Hatzimouratidis K. et al. Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med, 2016. 13: 465.
6. Yuan J. et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol, 2013. 63: 902.
